Experienced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome

Dr. Ilene C. Weitz

Hematology
1441 Eastlake Ave, 
Los Angeles, CA 
Experienced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
1441 Eastlake Ave, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ilene Weitz is a Hematologist in Los Angeles, California. Dr. Weitz is rated as an Experienced provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Autoimmune Hemolytic Anemia, Atypical Hemolytic Uremic Syndrome (aHUS), Splenectomy, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 51 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

1441 Eastlake Ave, Los Angeles, CA 90089

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).
An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).
Enrollment Status: Completed
Publish Date: January 08, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

51 Total Publications

Monotherapy with terminal pathway C5 inhibitors.
Monotherapy with terminal pathway C5 inhibitors.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 01, 2025
Similar Doctors
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Frank K. Mori
Oncology | Hematology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Frank K. Mori
Oncology | Hematology
390 North Pacific Coast Highway, Suite 1020, 
El Segundo, CA 
 (15.2 miles away)
310-649-7222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Frank Mori is a Hematologist and an Oncologist in El Segundo, California. Dr. Mori is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia. Dr. Mori is currently accepting new patients.

Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Chirag J. Dalsania
Hematology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Chirag J. Dalsania
Hematology
Camarillo, CA 
 (51.3 miles away)
805-485-8709
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chirag Dalsania is a Hematologist in Camarillo, California. Dr. Dalsania is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, and Polycythemia Vera. Dr. Dalsania is currently accepting new patients.

Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Kevin Q. Chang
Hematology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Kevin Q. Chang
Hematology
1700 North Rose Avenue, Suite 320, 
Oxnard, CA 
 (55.4 miles away)
805-485-8709
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Chang is a Hematologist in Oxnard, California. Dr. Chang is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Anemia, Schnitzler Syndrome, and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Chang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weitz's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 16 Advanced Conditions
View All 58 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile